I listened today and heard much of the same. As a long for several years, I've grown accustomed to finding the positive in the non-negative. The only thing we're waiting for is the (hopefully, successful) trial data and as long as they keep saying that that's on track (or slightly delayed...which it seems to be due to the difficulty screening candidates) I'm hearing positives. I believe the company is behind this product for the long haul and whether financing is dilutive or not, I'm in it for the long term. If it drops below $2 again, I'll buy more - every day we're a day closer to news and re-submission.